Yes NP also claims in recent IV that BP was unable to come up with the needed assay, and that is why we moved on to another vendor foe cancer trial. However InCelldx recently posted a white paper testing cancer cells for CCR5, so who knows. Maybe it was just slow coming.

I believe the other point of disagreement leading to the cooling of the relationship is that BP wanted to exclude mild Covid patients who didn't have elevated immunological biomarkers (i.e. RANTES) from the CD10 trial. Obviously they were let in, perhaps diluting the strength of the trial results. Perhaps results were still good enough to get approval. Will see what UK MHRA and FDA say.